2019 Novel Coronavirus by Qualitative PCR

INTERMOUNTAIN CENTRAL LABORATORY is now offering a molecular based assay for rapid detection of SARS-CoV-2 (aka COVID-19) viral RNA by Reverse Transcription Real Time PCR. This is an *in vitro* diagnostic test pending independent review from the FDA; it was developed by the CDC and adapted for clinical use by the Central Lab.

This test will be orderable beginning Monday, March 16, 2020.

ORDERING INFORMATION:	**Each patient order MUST be accompanied by the "2019 NOVEL CORONAVIRUS (SARS-CoV-2, COVID-19) QUALITATIVE PCR PATIENT HISTORY FORM"**
SPECIMEN COLLECTION:	**Nasopharyngeal swabs (Preferred)** Flocked swabs in viral transport media (VTM, UTM or M4) **Lower respiratory tract specimens** (If feasible) BAL, sputum, tracheal aspirates · 1-3 mL Sterile, preservative-free container **Nasopharyngeal aspirates or washes** (Accepted, NOT preferred) Sterile, preservative-free container · 1-3 mL
TRANSPORT:	Refrigerated
STABILITY:	Room temperature: 4 hours Refrigerated: 3 days Frozen: ≤ -70°C for 30 days
UNACCEPTABLE:	Nasal, nose, nostril, nares, mouth, tongue
PERFORMED / REPORTED:	Daily / Reported at test completion

Key Points

- A negative result does not necessarily exclude infection.
- Results should not be used as the sole basis of diagnosis, treatment or other patient management decisions.
- This panel detects three targets on the highly conserved SARS-CoV-2 nucleocapsid (N) gene.
- N1 & N2 targets are designed to specifically detect SARS-CoV-2.
- The N3 target is designed for the universal detection of SARS-like coronaviruses.
- Results Clarification:

Result	Targets Detected
Detected	All 3 Targets
Inconclusive	< 3 Targets
Indeterminant	Inhibitors likely present

Intermountain® Laboratory Services